Showing results (701-710 of 807) with videos related to

Sort By:
Pageof 81
Intensive Care Medicine|April 15, 2016
Comfort and patient-centred care without excessive sedation: the eCASH conceptJean-Louis Vincent, Yahya Shehabi, Timothy S Walsh, et al.
Critical Care Medicine|June 22, 2010
A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsisTodd W Rice, Arthur P Wheeler, Gordon R Bernard, et al.
The Lancet. Infectious Diseases|May 2, 2015
Sepsis: a roadmap for future researchJonathan Cohen, Jean-Louis Vincent, Neill K J Adhikari, et al.
Intensive Care Medicine|May 9, 2016
Less invasive hemodynamic monitoring in critically ill patientsJean-Louis Teboul, Bernd Saugel, Maurizio Cecconi, et al.
Critical Care (London, England)|December 24, 2010
Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated)Andrew F Shorr, Jonathan M Janes, Antonio Artigas, et al.
Critical Care Medicine|October 11, 2005
Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatmentJean-Louis Vincent, Gordon R Bernard, Richard Beale, et al.
BMC Anesthesiology|July 8, 2022
Assessing the discriminative ability of the respiratory exchange ratio to detect hyperlactatemia during intermediate-to-high risk abdominal surgeryLydia Karam, Olivier Desebbe, Sean Coeckelenbergh, et al.
Critical Care Medicine|February 10, 2021
Use of Biomarkers to Identify Acute Kidney Injury to Help Detect Sepsis in Patients With InfectionJohn A Kellum, Antonio Artigas, Kyle J Gunnerson, et al.
The Journal of Trauma|May 26, 2011
Recombinant activated factor VII safety in trauma patients: results from the CONTROL trialRichard P Dutton, Michael Parr, Bartholomew J Tortella, et al.
Critical Care Medicine|December 17, 2013
Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*Gordon R Bernard, Bruno Francois, Jean-Paul Mira, et al.
Pageof 81